With these products, the company eying a 400 per cent jump in sales from the Rs 8.5 crore turnover it notched last fiscal - its first year of operations here. "`We are looking at a revenue of Rs 40 crore this fiscal," Pharmacia & Upjohn India Pvt Ltd president and managing director Douglas J Herman told reporters. Around 10 per cent of the company's total income comes from its ophthalmology range.

Under the strategy, the company will unveil Caverject, a drug to treat erectile dysfunction, next year. Another product from the company's stable, to be launched this year, is Xalatan -- an eyedrop for treating glaucoma. All these products will be manufactured in Europe.

By the year 2000, the company will add two more pharmaceutical products to its existing range. Theseinclude Detrusitol, the urinary incontinence therapy product, and Reboxitine for treating depression.

The company also plans to set up local manufacturing facilities in the country. Declining to divulge details about future investment plans, Herman said: "We may enhance investments in the country, which will be brought in as equity."

Modalities for the proposed investments are being worked out. The proposed facilities will be utilised for manufacturing products in areas like female health-care, oncology, metabolic, critical care and infectious and cardiovascular diseases, Herman said.

The company, on Thursday, opened its first production facility at Nelamangala near Bangalore. The $8.8-million unit will produce the CeeOn brand intraocular lenses (IOLs) used to treat patients suffering from cataract. The facility will have a production capacity of five lakh pieces per annum. Since the total production will be earmarked for domestic purposes, there will be no exports of IOLs from the country.

Hermansaid intraocular lenses made in the country at present are all three-piece, whereas the IOLs to be manufactured in the new facility will be one-piece. Three-piece IOLs serve the same purpose as one-piece IOLs, but are more difficult to use and likely to cause complications after surgery, he added.

The company in association with the Karnataka Ophthalmological Society will sponsor a symposium on glaucoma and phacoemulsification in Bangalore shortly.